Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Epigallocatechin, most commonly found as epigallocatechin gallate (EGCG) in green tea, has been researched for its potential gastroprotective properties in the context of ulcer prevention and treatment. Preclinical studies in animal models suggest that EGCG can reduce gastric mucosal injury caused by ethanol, indomethacin, and stress by acting as an antioxidant, reducing inflammation, and promoting mucosal healing. These effects are attributed to its ability to scavenge reactive oxygen species, inhibit pro-inflammatory cytokines, and enhance the production of protective gastric mucus. Some in vitro studies indicate that EGCG may also inhibit the growth of Helicobacter pylori, a bacterium linked to peptic ulcer disease. However, clinical evidence in humans is limited and largely inconclusive. There are few, if any, robust randomized controlled trials directly evaluating EGCG for ulcer treatment or prevention in humans. Most published data are from laboratory or animal research, and thus the translation to clinical practice remains unclear. Overall, while there is a plausible biological mechanism and some supportive preclinical data for EGCG’s use in ulcer support, the evidence is not strong or definitive. Clinical recommendations cannot be made at this time, and more high-quality human studies are needed to confirm any therapeutic benefit.

More about Epigallocatechin
More about Ulcers

Other ingredients used for Ulcers

Other health conditions supported by Epigallocatechin

Products containing Epigallocatechin